Abstract
This study represents the first comprehensive investigation into the repertoire of human serum antibody responses against the whole-cell pertussis vaccine (WCV). Utilizing a classic immunoproteomic strategy, researchers identified a small number of previously uncharacterized antigens of Bordetella pertussis (B.p). The identification of these predominant antigens, which appear specific to the human immune response, is expected to accelerate the development of diagnostic biomarkers and next-generation subunit vaccines. Furthermore, this work provides critical insights into human immunity mechanisms against WCV, specifically highlighting the significant heterogeneity between immunoreactivity patterns in mouse models versus human hosts.
Introduction: Addressing the Knowledge Gap in Pertussis Immunity
Pertussis, commonly known as whooping cough, is caused by the bacterium Bordetella pertussis. Despite widespread vaccination programs, it remains a significant global health challenge. Current efforts to develop more effective "next-generation" subunit vaccines require a precise understanding of which bacterial proteins are targeted by the human immune system.
Historically, vaccine research has heavily relied on murine (mouse) models. However, B.p is a strictly human pathogen, and the disease manifestation in mice does not perfectly mirror human infection. Consequently, there has been a substantial knowledge gap regarding the specific "repertoire" of human serological antibody responses. This study aims to bridge this gap by mapping the specific proteins within the whole-cell vaccine that are recognized by human antibodies.
Methodology: A Multi-Step Immunoproteomic Approach
To identify these antigens, the researchers employed a high-resolution immunoproteomic strategy:
- Protein Extraction: Two distinct protein groups were isolated from the Chinese WCV strain 58003: Total Membrane-enriched Proteins (TMPs) and Extracellular Proteins (ECPs). These fractions contain the proteins most likely to be exposed to and interact with the host immune system.
- Two-Dimensional Electrophoresis (2-DE): Extracted proteins were separated on a gel based on two properties: their isoelectric point (electrical charge) and their molecular weight. This allowed for the resolution of complex protein mixtures into individual "spots."
- Immunoblotting: The separated proteins were transferred to a membrane and probed with pooled serum from children who had received the WCV. This step visually identified which specific protein spots were reactive with human antibodies.
- Mass Spectrometry (MALDI-TOF-MS): Reactive spots were excised from the gel and analyzed via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry to determine their unique peptide sequences and identify the proteins.
- Bioinformatics and Expression Analysis: Computational tools were used to predict subcellular localization and analyze the Codon Adaptation Index (CAI) to estimate protein expression levels, providing context for why certain proteins might be more immunogenic.
Data Sources and Comparative Analysis
The study integrated several data streams:
- Primary Proteomic Profiles: Generated directly from the B. pertussis Chinese WCV strain 58003.
- Comparative Murine Data: Immunoproteomes from mouse models (Saadet and Tohama strains) were sourced from existing literature to facilitate a cross-species comparison.
- Reference Databases: Protein identification was performed using the NCBI database via MASCOT, while Pfam was utilized for protein family classification. Transcriptional profiling data from ArrayExpress (EBI) was used to correlate protein presence with gene expression.
Discussion: The Human-Mouse Disconnect
The most striking finding of this research is the lack of overlap between human and murine immune responses. Of the proteins identified, only four were recognized by both species. This discrepancy suggests that vaccine candidates selected based solely on mouse data may fail to include the most potent antigens for human protection.
The study identified 30 distinct immunoreactive proteins. While seven were established pertussis antigens (such as Pertactin and GroEL), 16 were known to be immunogenic in other bacterial species but had never been linked to the human response to B.p. Most notably, seven proteins were identified as immunogenic for the first time in any organism. Interestingly, many of these antigens are "housekeeping" enzymes involved in basic metabolism. Because these proteins are highly conserved, they represent promising candidates for universal vaccines that remain effective even as bacterial strains evolve.
Key Results
- Identification of 30 Antigens: The study successfully mapped 30 proteins that trigger a human antibody response.
- Subcellular Distribution: Analysis showed that 37% of these antigens are associated with the outer membrane, while 47% are cytoplasmic.
- Validation and Discovery: The research confirmed the presence of major known protective antigens like Pertactin (Prn) and Serum resistance protein (BrkA), while simultaneously discovering 23 novel immunoreactive proteins that react uniquely with human serum.
Conclusion and Future Directions
While 2-DE is a powerful tool, it has limitations, such as difficulty resolving very large proteins (like Filamentous hemagglutinin), highly basic proteins, or low-abundance proteins like the Pertussis Toxin. This explains why some known antigens were not captured in this specific screen. Additionally, the use of pooled serum provides a generalized view of the immune response, potentially masking individual variability.
The next phase of this research involves "reverse vaccinology"—systematically testing the 30 identified proteins in clinical models to determine which provide the most robust protection. This library of human-specific antigens provides a critical foundation for developing more refined, safer, and more effective acellular pertussis vaccines.
Summary updated